ArticleJournal of translational medicine2026
Diagnostic evaluation and clinical utility of C-MoKa for prenatal genetic testing.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundC-MoKa (Chromosome Conformation-based Karyotyping) is a novel 3D genome mapping platform, that enables simultaneous detection of structural variations (SVs), aneuploidies, copy number variations (CNVs), and uniparental disomy (UPD) in a single test. However, its performance in routine prenatal diagnosis is still unexplored. This study aimed to comprehensively evaluate the diagnostic performance and clinical utility of C-MoKa in prenatal diagnosis, and to assess its technical concordance with standard of care (SOC) testings in prenatal diagnosis.
methodsA two-phase study was designed. In phase 1, 56 retrospective participants with known chromosomal abnormalities (CAs) were recruited, and C-MoKa was performed on their cultured amniotic fluid (AF) samples. Concordance between C-MoKa and known CAs was analyzed. In phase 2, a prospective cohort of 208 participants for prenatal diagnosis were recruited. Samples underwent C-MoKa and karyotyping (KT), with parallel chromosomal microarray analysis (CMA) or improved whole-exome sequencing (iWES). In our study, supplementary copy number probes were enhanced in iWES detection, which could provide ~ 100 kb resolution across the genome, thus either CMA or iWES platform employed was used to assess the CNV detection. Diagnostic yields and concordance were evaluated, and the discordance of SVs and CNVs were further validated by fluorescence in situ hybridization (FISH) and CNV-seq, respectively.
resultsIn the retrospective cohort with known CAs, C-MoKa achieved a 94.6% (53/56) diagnostic yield and 92.8% (52/56) concordance with KT + CNV. In the prospective cohort, its diagnostic yield was 21.2% (44/208), higher than KT (12.5%, 26/208) and CNV (18.3%, 38/208). The diagnostic yield (22.6%, 47/208) was achieved when CNV platform and C-MoKa were used together. C-MoKa exhibited concordance rates of 89.4% (186/208) with KT, 89.9% (187/208) with CNV, and 90.4% (188/208) with KT + CNV. Two SVs identified by C-MoKa but missed by KT were successfully determined by FISH, and five samples with additional CNVs identified by C-MoKa were consistently detected by CNV-seq.
conclusionsOur findings demonstrate that C-MoKa is a highly effective and reliable method for prenatal diagnosis, exhibiting high concordance with SOC techniques. Compared to the conventional application of "KT + CNV" in prenatal setting, the combined use of CNV and C-MoKa appears to maximize the diagnostic yield.
Indexed as
Identifiers
42449384What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.